Ausgabe 2/2019
Safety of novel anticancer therapies: Future perspectives
Inhalt (11 Artikel)
Review Article
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
Review Article
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah, Devron R. Shah
Review Article
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Danilo Rocco, Ciro Battiloro, Luigi Della Gravara, Cesare Gridelli
Review Article
Safety and Tolerability of c-MET Inhibitors in Cancer
Alberto Puccini, Nagore I. Marín-Ramos, Francesca Bergamo, Marta Schirripa, Sara Lonardi, Heinz-Josef Lenz, Fotios Loupakis, Francesca Battaglin
Review Article
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
Review Article
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
Giuseppe Curigliano, Rashmi R. Shah
Review Article
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer
Richard L. Carpenter, Haimanti Ray
Review Article
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Iosune Baraibar, Ignacio Melero, Mariano Ponz-Sarvise, Eduardo Castanon
Open Access
Review Article
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska-Washer, Tadeusz Robak
Review Article
Safety and Tolerability of Adoptive Cell Therapy in Cancer
Benita Wolf, Stefan Zimmermann, Caroline Arber, Melita Irving, Lionel Trueb, George Coukos